1.
Larson ST, Ray BE, Wilbur J. Ischemic stroke management: posthospitalization and transition of care. Am Fam Physician. 2023;108(1):70-77.
2.
Saini V, Guada L, Yavagal DR. Global epidemiology of stroke and access to acute ischemic stroke interventions. Neurology. 2021;97(20_Supplement_2):S6-S16.
3.
Qiu L, Fu F, Zhang W, He J, Zhan Z, Cheng Z. Prevalence, risk factors, and clinical outcomes of remote intracerebral hemorrhage after intravenous thrombolysis in acute ischemic stroke: a systematic review and meta-analysis. J Neurol. 2023; 270(2):651-661. doi:10.1007/s00415-022-11414-2
4.
Zhang B, Lei H, Ambler G, et al. Association between triglyceride-glucose index and early neurological outcomes after thrombolysis in patients with acute ischemic stroke. J Clin Med. 2023;12(10):3471. doi:10.3390/jcm12103471
5.
Liu H, Liu D, Zuo P. Association between insulin resistance markers and poor prognosis in patients with acute ischemic stroke after intravenous thrombolysis. Neurologist. 2024;29(4):218-224. doi:10.1097/nrl.0000000000000550
6.
Yang Y, Huang X, Wang Y, et al. The impact of triglyceride-glucose index on ischemic stroke: a systematic review and meta-analysis. Cardiovasc Diabetol. 2023;22(1):2-13. doi:10.1186/s12933-022-01732-0
7.
Hou Z, Pan Y, Yang Y, et al. An Analysis of the potential relationship of triglyceride glucose and body-mass index with stroke prognosis. Front Neurol. 2021;12:630140. doi:10.3389/fneur. 2021.630140
8.
Ding PF, Zhang HS, Wang J, et al. Insulin resistance in ischemic stroke: mechanisms and therapeutic approaches. Front Endocrinol (Lausanne). 2022;13:1092431. doi:10.3389/fendo.2022. 1092431
9.
Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299-304. doi:10.1089/met. 2008.0034
10.
Park HM, Lee HS, Lee YJ, Lee JH. The triglyceride-glucose index is a more powerful surrogate marker for predicting the prevalence and incidence of type 2 diabetes mellitus than the homeostatic model assessment of insulin resistance. Diabet Res Clin Pract. 2021;180:109042.
11.
Lin SF, Hu HH, Chao HL, et al. Triglyceride-glucose index and intravenous thrombolysis outcomes for acute ischemic stroke: a multicenter prospective-cohort study. Front Neurol. 2022;13: 737441. doi:10.3389/fneur.2022.737441
12.
Toh EMS, Lim AYL, Ming C, et al. Association of triglyceride-glucose index with clinical outcomes in patients with acute ischemic stroke receiving intravenous thrombolysis. Sci Rep. 2022;12(1):1596. doi:10.1038/s41598-022-05467-6
13.
Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-282. doi:10. 1016/s0140-6736(07)60149-4
14.
Wu Y, Yang Y, Zhang J, Liu S, Zhuang W. The change of triglyceride-glucose index may predict incidence of stroke in the general population over 45 years old. Cardiovasc Diabetol. 2023; 22(1):132. doi:10.1186/s12933-023-01870-z
15.
Calleja AI, García-Bermejo P, Cortijo E, et al. Insulin resistance is associated with a poor response to intravenous thrombolysis in acute ischemic stroke. Diabetes Care. 2011;34(11):2413-2417. doi:10.2337/dc11-1242
16.
Shimobayashi M, Albert V, Woelnerhanssen B, et al. Insulin resistance causes inflammation in adipose tissue. J Clin Invest. 2018;128(4):1538-1550. doi:10.1172/jci96139
17.
Jin R, Liu L, Zhang S, Nanda A, Li G. Role of inflammation and its mediators in acute ischemic stroke. J Cardiovasc Transl Res. 2013;6(5):834-851. doi:10.1007/s12265-013-9508-6
18.
Huang YW, Yin XS, Li ZP. Association of the systemic immune-inflammation index (SII) and clinical outcomes in patients with stroke: a systematic review and meta-analysis. Front Immunol. 2022;13:1090305. doi:10.3389/fimmu.2022.1090305
19.
Ma F, Li L, Xu L, et al. The relationship between systemic inflammation index, systemic immune-inflammatory index, and inflammatory prognostic index and 90-day outcomes in acute ischemic stroke patients treated with intravenous thrombolysis. J Neuroinflammation. 2023;20(1):220. doi:10.1186/s12974-023-02890-y
20.
Palomo I, Alarcón M, Moore-Carrasco R, Argilés JM. Hemostasis alterations in metabolic syndrome (review). Int J Mol Med. 2006; 18(5):969-974.
21.
Bas DF, Ozdemir AO, Colak E, Kebapci N. Higher insulin resistance level is associated with worse clinical response in acute ischemic stroke patients treated with intravenous thrombolysis. Transl Stroke Res. 2016;7(3):167-171. doi:10.1007/s12975-016-0453-y
22.
Rao NM, Levine SR, Gornbein JA, Saver JL. Defining clinically relevant cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the National Institute of Neurological Disorders and Stroke tissue-type plasminogen activator trials. Stroke. 2014;45(9):2728-2733. doi:10.1161/strokeaha.114.005135